GHRP-2: what the studies show

Japan's diagnostic product

GHRP-2 is pralmorelin. Japan's GHRP Kaken 100 product contains pralmorelin hydrochloride and is authorized to diagnose growth hormone deficiency. Its label describes an intravenous stimulation test with timed blood sampling. The authorization covers a supervised diagnostic session, not ongoing treatment. There is no FDA-approved GHRP-2 human drug product.

The short-term experiment

A randomized placebo-controlled study enrolled 19 healthy, weight-stable adults, including nine with obesity. During 270-minute visits, subcutaneous GHRP-2 infusion increased growth hormone release and food intake. The largest studied exposure increased buffet-meal intake by about one third compared with placebo.

The study measured short-term appetite and hormone responses. It does not show that repeated use builds muscle, reduces fat, improves function, or extends life. The study infusion and Japanese intravenous diagnostic product are not established as interchangeable.

Missing treatment evidence

Long-term treatment requires patient outcomes and safety evidence beyond a hormone response. FDA retains safety concerns for injectable and nasal GHRP-2 preparations. For a diagnostic record, sample times and the assay method matter because the Japanese label ties interpretation to both.